Merck KGaA : Q1 in line, detailed FY guidance provides upside
>Healthcare keeping up well, strong margin in Life Science - The company showed the expected strong start to 2022 with sales having increased by 12% y-o-y and adj. EBITDA by 8%, in line with our forecast and consensus (Vara). Organic sales growth was 7.8% y-o-y with FX having provided tailwind of 4.4% y-o-y. This compares to our forecast of 8.5% y-o-y organic sales growth and +3.5% y-o-y coming from FX. Hence, the mix was a bit different. The core driver was Life Sci...Merck is a global science and technology company based in Germany. Co. diversifies its activities into four business divisions: Merck Serono, Consumer Health, Performance Materials and Merck Millipore. The Merck Serono develops, manufactures and markets prescription drugs to treat cancer, multiple sclerosis, infertility, growth disorders, and selected cardiovascular and metabolic diseases. The Consumer Health manufactures and markets over-the-counter drugs addressing health themes such as mobility, women's and children's health, cough and cold. Performance Materials is a specialty chemicals business. The Merck Millipore is the supplier of products and services for the life science industry.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.